Invivyd (IVVD) Operating Income (2021 - 2026)
Invivyd's (IVVD) quarterly Operating Income came in at -$45.8 million in Q2 2026, down 204.25% on a YoY basis from $44.0 million in Q2 2025, and down 264.95% quarter-over-quarter from -$12.6 million in Q4 2025.
Analysis
Invivyd (IVVD) Operating Income (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Operating Income for 6 consecutive years, with -$45.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Income fell 204.25% year-over-year to -$45.8 million; the trailing twelve-month figure through Jun 2026 stood at -$84.5 million (up 25.6% YoY), and the FY2025 full-year result was -$55.6 million, up 68.59% from the prior year.
- Operating Income declined to -$45.8 million in Q2 2026 per IVVD's latest filing, from -$12.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$11.0 million in Q3 2025 and bottomed at -$100.7 million in Q1 2022.
- Historically, Operating Income has averaged -$43.5 million across 5 years, with a median of -$46.1 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Operating Income jumped 82.31% in 2025, then plunged 204.25% in 2026.
- Over 5 years, Operating Income stood at -$48.2 million in 2022, then sank by 59.2% to -$76.8 million in 2023, then surged by 74.95% to -$19.2 million in 2024, then surged by 34.71% to -$12.6 million in 2025, then plunged by 264.95% to -$45.8 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$45.8 million, -$12.6 million, and -$11.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | -45.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.82 Mn |
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -16.92 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -62.31 Mn |
| Jun 30, 2024 | -49.25 Mn |
| Mar 31, 2024 | -46.09 Mn |
| Dec 31, 2023 | -76.75 Mn |
| Sep 30, 2023 | -43.06 Mn |
| Jun 30, 2023 | -53.88 Mn |
| Mar 31, 2023 | -39.07 Mn |
| Dec 31, 2022 | -48.21 Mn |
| Sep 30, 2022 | -47.33 Mn |
| Jun 30, 2022 | -51.75 Mn |
| Mar 31, 2022 | -100.74 Mn |
| Dec 31, 2021 | -83.09 Mn |
| Sep 30, 2021 | -60.42 Mn |
| Jun 30, 2021 | -44.69 Mn |